Premium
Loss of XRCC 1 confers a metastatic phenotype to melanoma cells and is associated with poor survival in patients with melanoma
Author(s) -
Bhandaru Madhuri,
Martinka Magdalena,
Li Gang,
Rotte Anand
Publication year - 2014
Publication title -
pigment cell and melanoma research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.618
H-Index - 105
eISSN - 1755-148X
pISSN - 1755-1471
DOI - 10.1111/pcmr.12212
Subject(s) - melanoma , cancer research , medicine , tissue microarray , xrcc1 , metastasis , mucosal melanoma , phenotype , cancer , pathology , oncology , biology , gene , genotype , genetics , single nucleotide polymorphism
Summary Ultraviolet (UV) radiation‐induced DNA damage and genomic instability is one of the leading causes for melanoma. X‐ray repair cross‐complementary protein 1, XRCC 1, plays a critically important role in base excision repair pathway. This study was therefore performed to analyze the correlation between XRCC 1 expression, melanoma progression, and patient survival. Using a tissue microarray with a total of 119 patients with melanoma, we demonstrate that loss of XRCC 1 expression is associated with the progression of disease from dysplastic nevi to primary melanoma and to metastatic melanoma. We found that the loss of XRCC 1 was correlated with the progression of melanoma from AJCC stage II to stage III and with worse overall and disease‐specific 5‐yr and 10‐yr survival of patients with melanoma. Furthermore, we also illustrate the inhibitory effect of XRCC 1 on melanoma cell invasion and migration, which are the regulatory events in melanoma metastasis.